In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains ofHaemophilus influenzae
| Autor: | M. Bernier, M. G. Bergeron, J. L'Ecuyer |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Microbiology (medical)
Canada Haemophilus Infections medicine.drug_class Metabolite Antibiotics Drug Evaluation Preclinical Erythromycin Microbial Sensitivity Tests Biology medicine.disease_cause beta-Lactamases Haemophilus influenzae Microbiology chemistry.chemical_compound Clarithromycin polycyclic compounds medicine Humans Antibacterial agent Pasteurellaceae Drug Synergism General Medicine biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Bacterial Typing Techniques Infectious Diseases chemistry Drug Therapy Combination Antagonism medicine.drug |
| Zdroj: | Infection. 20:164-167 |
| ISSN: | 1439-0973 0300-8126 |
| DOI: | 10.1007/bf01704612 |
| Popis: | The in vitro activity of clarithromycin alone and in combination with its primary human metabolite, 14-hydroxy-clarithromycin, was determined against 203 strains of Haemophilus influenzae. Microdilution broth MICs and MBCs of both clarithromycin and 14-hydroxy-clarithromycin were determined. The clarithromycin MIC50 was 4 mg/l and the MIC90 was 8 mg/l. The hydroxy metabolite was 2-4-fold more active with an MIC50 and MIC90 of 2 mg/l. The MBCs were equal to the MICs. The microbicidal effect of combinations of clarithromycin and 14-hydroxy-clarithromycin was tested using a microdilution checkerboard technique and the fractional inhibitory index was calculated. The combination was additive in 92% and synergistic in 8% of all strains of H. influenzae tested; no antagonism was found. The results were independent of the site of isolation of the strain or presence of beta-lactamase. These findings suggest the potential clinical utility of clarithromycin for the treatment of H. influenzae infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink